KaydedilenlerDerginizi ekleyin

Dergiler / Moment Dergi / 2022 / Cilt: 9 - Sayı: 1

The Effect of Transurethral Resection and BCG Therapy on Cytokine Levels in Non-Muscle Invasive Bladder Cancer

Oktay ÜÇER
Gökhan TEMELTAŞ
Talha MÜEZZİNOĞLU
Zeki ARI
Funda KOSOVA
Sayfa
154–158
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The mean of preoperative IL-1 and neopterin levels significantly decreased after TURBT (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The present study investigated the effect of treatment on interleukin (IL)-1, IL-6, IL-8, and neopterin levels in patients with non-muscle invasive bladder cancer (NMIBC).
📊
Temel Bulgular & Veri:Materials and Methods: Thirty patients with NMIBC and 30 age-matched controls were included in the study.
💡
Sonuç & Katkı:The mean of preoperative IL-1 and neopterin levels significantly decreased after TURBT (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: The present study investigated the effect of treatment on interleukin (IL)-1, IL-6, IL-8, and neopterin levels in patients with non-muscle invasive bladder cancer (NMIBC). Materials and Methods: Thirty patients with NMIBC and 30 age-matched controls were included in the study. Preoperative, postoperative first control [at two weeks after second transurethral resection of bladder tumor (TURBT)] and the second control (at the end of intravesical immunotherapy) blood samples were analyzed using ELISA to determine IL-1, IL-6, IL-8, and neopterin levels. The mean cytokine levels of the patients were statistically compared and comparing the patients’ and controls’ levels. Results: There were no statistically significant differences between the mean IL-1, IL-6, IL-8, and neopterin levels of the patient and control groups before initial TURBT. In the patient group, there were no statistically significant differences in the IL-6 and IL-8 levels after both TURBT and intravesical Bacillus Calmette-Guérin (BCG) therapy. The mean of preoperative IL-1 and neopterin levels significantly decreased after TURBT (p

🔖

Bu Makaleye Atıf Yap

ÜÇER, O., TEMELTAŞ, G., MÜEZZİNOĞLU, T., ARI, Z., KOSOVA, F. (2022). The Effect of Transurethral Resection and BCG Therapy on Cytokine Levels in Non-Muscle Invasive Bladder Cancer. Moment Dergi, Cilt: 9 - Sayı: 1, 154–158. https://ajindex.com/articles/581649

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, Zigeuner R, Capoun O, Cohen D, Escrig JLD, Hernández V, Peyronnet B, Seisen T, Soukup V. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019;76:639-657
  2. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-256
  3. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216-1223
  4. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682-686; discussion 686-687
  5. Sylvester RJ, van der MEIJDEN AP, Lamm DL. Intravesical bacillus Calmette- Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-1970
  6. Temeltaş G, Kosova F, Üçer O, Müezzinoğlu T, Arı Z. Effects of Treatment on Angiogenic (Vascular Endothelial Growth Factor-2 and Matrix Metalloproteinase-2) and Antiangiogenic (Endostatin and Thrombospondin-1) Factors in Non-muscle Invasive Bladder Carcinoma. J Urol Surg 2017;4:71-75
  7. Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat A. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in nonmuscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology 2017;6:e1265719
  8. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170:964-969
  9. Takeuchi A, Dejima T, Yamada H, Shibata K, Nakamura R, Eto M, Nakatani T, Naito S, Yoshikai Y. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer. Eur J Immunol 2011;41:246-251
  10. Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu J. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients.